Gilead to Buy Arcellx in $8B CAR‑T Deal
February 23, 2026
Gilead is set to acquire Arcellx for about $7.8–8B in cash, paying roughly $115 per share and positioning its multiple myeloma CAR‑T against J&J’s Carvykti.
February 23, 2026
Gilead is set to acquire Arcellx for about $7.8–8B in cash, paying roughly $115 per share and positioning its multiple myeloma CAR‑T against J&J’s Carvykti.